RH
XMUN:RS1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
RH
XMUN:RS1
|
US |
|
V
|
Vertex Pharmaceuticals Inc
BMV:VRTX
|
US |
|
S
|
Stroeer SE & Co KgaA
XMUN:SAX
|
DE |
|
D
|
DSV A/S
SWB:DS81
|
DK |
|
S
|
Salesforce Inc
XMUN:FOO
|
US |
|
F
|
Fifth Third Bancorp
DUS:FFH
|
US |
|
S
|
Synchrony Financial
SWB:SFE
|
US |
|
Brookfield Wealth Solutions Ltd
TSX:BNT
|
BM |
|
C
|
China Resources Land Ltd
XMUN:CHZ
|
HK |
|
G
|
Grammer AG
LSE:0OQX
|
DE |
Wall St Price Targets
RS1 Price Targets Summary
RH
According to Wall Street analysts, the average 1-year price target for RS1 is 130.01 EUR with a low forecast of 74.87 EUR and a high forecast of 212.27 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RS1's stock price target?
Price Target
130.01
EUR
According to Wall Street analysts, the average 1-year price target for RS1 is 130.01 EUR with a low forecast of 74.87 EUR and a high forecast of 212.27 EUR.
What is the Revenue forecast for RH?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for RH?
Projected CAGR
14%
Over the last 14 years, the compound annual growth rate for Operating Income has been 21%. The projected CAGR for the next 8 years is 14%.
What is the Net Income forecast for RH?
Projected CAGR
36%
Over the last 14 years, the compound annual growth rate for Net Income has been 14%. The projected CAGR for the next 8 years is 36%.
